Table 25 Top 10 pairs of drugs with their correlation with respect to TN breast cancer subtype, both when they are combined and individually
From: Computationally repurposing drugs for breast cancer subtypes using a network-based approach
Drug1 | Drug2 | C. Cor. | Cor. 1 | Cor. 2 | C. Rank | Rank 1 | Rank 2 |
|---|---|---|---|---|---|---|---|
Bromocriptine | Isradipine | − 0.85 | − 0.57 | − 0.47 | 1 | 10 | 51 |
Cinepazide | Vidarabine | − 0.80 | − 0.45 | − 0.45 | 2 | 74 | 75 |
Bromocriptine | Emtricitabine | − 0.79 | − 0.57 | − 0.56 | 3 | 10 | 13 |
Bromocriptine | Etofylline-Clofibrate | − 0.77 | − 0.57 | − 0.51 | 4 | 10 | 22 |
Emtricitabine | Finasteride | − 0.76 | − 0.56 | − 0.50 | 5 | 13 | 26 |
JTC-801 | Telatinib | − 0.75 | − 0.55 | − 0.47 | 6 | 16 | 47 |
Ruxolitinib | Dalfampridine | − 0.74 | − 0.77 | − 0.50 | 7 | 1 | 31 |
Semaxanib | Isradipine | − 0.74 | − 0.59 | − 0.47 | 8 | 7 | 51 |
Ruxolitinib | Pregnenolone | − 0.74 | − 0.77 | − 0.48 | 9 | 1 | 40 |
Tadalafil | Acyclovir | − 0.74 | − 0.47 | − 0.46 | 10 | 43 | 58 |